ASGN Inc logo

ASGN - ASGN Inc News Story

$102.8 2.0  1.9%

Last Trade - 14/05/21

Sector
Technology
Size
Large Cap
Market Cap £3.88bn
Enterprise Value £4.34bn
Revenue £2.83bn
Position in Universe 1319th / 6846

U.S. RESEARCH ROUNDUP- Allovir, Facebook, Vertex

Mon 24th August, 2020 8:01am
Aug 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Allovir, Facebook and Vertex on Monday. 
    
    HIGHLIGHTS
     * Allovir Inc  ALVR.O : JP Morgan starts with overweight rating; target price $50
     * Facebook Inc  FB.O : Jefferies raises target price to $310 from $300
     * Vertex Inc  VERX.O : Jefferies starts with buy rating; target price $34
        
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
    
     * Allovir Inc  ALVR.O : JP Morgan starts with overweight rating; target price $50
     * ASGN Inc  ASGN.N : Jefferies raises target price to $72 from $54
     * Brighthouse Financial Inc  BHF.O : Evercore ISI raises target price to $44 from $40
     * Deere & Co  DE.N : RBC raises target price to $228 from $180
     * Dick's Sporting Goods Inc  DKS.N : JP Morgan raises target price to $52 from $41
     * Facebook Inc  FB.O : Jefferies raises target price to $310 from $300
     * Fiesta Restaurant Group Inc  FRGI.O : Piper Sandler raises target price to $10 from $8
     * Howard Hughes Corp  HHC.N : Jefferies raises target price to $82 from $80
     * IRhythm Technologies Inc  IRTC.O : JP Morgan raises target price to $235 from $140
     * Lululemon Athletica Inc  LULU.O : Susquehanna raises target price to $426 from $360
     * Principal Financial Group Inc  PFG.O : Credit Suisse raises target price to $46 from $43
     * Vertex Inc  VERX.O : Jefferies starts with buy rating; target price $34
     * Williams-Sonoma Inc  WSM.N : JP Morgan raises target price to $89 from $75
 

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.